Clinical Trial Update: Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial update on long-term safety and tolerability of 0.5 mg fingolimod in relapsing forms of multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Forms of Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Forms of Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2019-11-07